INSILICO (03696.HK): Enters CNS Drug R&D Collaboration with Cosmo Pharmaceutical, Potential Milestone Payments Up to Approximately RMB1.2 Billion
NewTimeSpace News: INSILICO (03696.HK) announced on 13 July that the Group has entered into a new strategic cooperation for central nervous system drug research and development with Cosmo Pharmaceutical Holdings Limited. Leveraging INSILICO’s AI platform and Cosmo’s profound disease expertise, both parties will jointly advance innovative drug development. INSILICO is eligible to receive milestone payments of up to approximately RMB1.2 billion in aggregate, plus net sales royalties. The Company reminded investors that forward-looking statements are not guaranteed to materialise and shareholders should exercise caution when trading shares.
NewTimeSpace News: On 13 July 2026, INSILICO (03696.HK) released a voluntary announcement that the Group has entered into a new strategic collaboration for central nervous system (CNS) drug research and development with CMS Holdings Limited.
Under the agreement, both parties will integrate INSILICO’s AI platform and CMS’s profound understanding of disease areas to jointly carry out cooperative development of innovative medicines. INSILICO may receive aggregate milestone payments of up to approximately RMB1.2 billion, together with royalties based on net sales.
CMS (00867.HK) is dual-listed in Hong Kong and Singapore, focusing on specialty sectors including cardiovascular, renal and metabolism, gastroenterology, ophthalmology and dermatology. INSILICO stated the collaboration will utilise its validated AI platform to accelerate novel drug discovery.
The Company cautions that there is no guarantee the forward-looking statements contained in this announcement will materialise. Shareholders and investors shall exercise prudence when trading the Company’s shares.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- InSilico Medicine (03696.HK): Expects to Turn Profit in H1, Net Profit of US$33.5M to US$39.5M
- INSILICO(03696.HK): Phase III Clinical Trial of Rentosertib for Idiopathic Pulmonary Fibrosis Officially Launched
- INSILICO(03696.HK) Enters AI-Powered R&D Collaboration with SK Biopharmaceuticals, Total Potential Deal Value Exceeds USD2.5 Billion
- INSILICO(03696.HK) closed 10.1% higher
- INSILICO(03696.HK) closed 14.06% higher, The full-day turnover stood at HKD 618.6 million
